American Medical Innovation and Investment Act of 2024 (Sec. 5)

Mandates the Secretary of Health and Human Services to issue guidance on required Medicare payment for continuous glucose monitors by January 1, 2026. Specifies that the use AI components like continuous adjustment. Requires that these devices transmit information to healthcare providers for management and treatment purposes.

Paper

Full text

PDF

American Medical Innovation and Investment Act of 2024 (Sec. 5)

ETO AGORA · U.S. federal laws · 2024

Summary

Mandates the Secretary of Health and Human Services to issue guidance on required Medicare payment for continuous glucose monitors by January 1, 2026.

Specifies that the use AI components like continuous adjustment.

Requires that these devices transmit information to healthcare providers for management and treatment purposes.

Requires issuing guidance on Medicare payments for AI-based remote monitoring devices by January 1, 2026.

SEC. 5. GUIDANCE ON MEDICARE PAYMENT FOR CERTAIN ITEMS INVOLVING ARTIFICIAL INTELLIGENCE. Not later than January 1, 2026, the Secretary of Health and Human Services shall use existing communications mechanisms to issue guidance on requirements for payment under part B of title XVIII of the Social Security Act (42 U.S.C. 1395j et seq.) for remote monitoring devices, such as continuous glucose monitors, that— (1) use an artificial intelligence component (such as a continuous adjustment component); and (2) transmit information to a health care provider for purposes of management and treatment of an individual.

Similar papers

© 2026 NYSGPT2525 LLC